共查询到20条相似文献,搜索用时 15 毫秒
1.
Berenson JR Boccia R Siegel D Bozdech M Bessudo A Stadtmauer E Talisman Pomeroy J Steis R Flam M Lutzky J Jilani S Volk J Wong SF Moss R Patel R Ferretti D Russell K Louie R Yeh HS Swift RA 《British journal of haematology》2006,135(2):174-183
We assessed the safety and efficacy of melphalan, arsenic trioxide (ATO) and ascorbic acid (AA) (MAC) combination therapy for patients with multiple myeloma (MM) who failed more than two different prior regimens. Patients received melphalan (0.1 mg/kg p.o.), ATO (0.25 mg/kg i.v.) and AA (1 g i.v) on days 1-4 of week 1, ATO and AA twice weekly during weeks 2-5 and no treatment during week 6 of cycle 1; during cycles 2-6, the schedule remained the same except ATO and AA were given twice weekly in week 1. Objective responses occurred in 31 of 65 (48%) patients, including two complete, 15 partial and 14 minor responses. Median progression-free survival and overall survival were 7 and 19 months respectively. Twenty-two patients had elevated serum creatinine levels (SCr) at baseline, and 18 of 22 (82%) showed decreased SCr levels during treatment. Specific grade 3/4 haematological (3%) or cardiac adverse events occurred infrequently. Frequent grade 3/4 non-haematological adverse events included fever/chills (15%), pain (8%) and fatigue (6%). This steroid-free regimen was effective and well tolerated in this heavily pretreated group. These results indicate that the MAC regimen is a new therapeutic option for patients with relapsed or refractory MM. 相似文献
2.
Richard A. Campbell Eric Sanchez Jeffrey Steinberg Dror Shalitin Zhi‐Wei Li Haiming Chen James R. Berenson 《European journal of haematology》2010,84(3):201-211
Objectives: Examine the antitumor activity of the histone deacetylase inhibitor vorinostat’s antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model. Methods: RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan, or bortezomib alone, or combinations of vorinostat with melphalan or bortezomib. Cell proliferation was measured using the MTS [3‐(4,5‐dimethylthiazol‐2yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfphophenyl)‐2H‐tetrazolium, inner salt] assay. Severe combined immunodeficient mice bearing LAGκ‐1B tumors were treated with vorinostat [30, 60, or 100 mg/kg daily for five consecutive days per week (qd×5d), 100 or 300 mg/kg daily for 2 d/wk (qd×2d)], melphalan (1, 3, or 10 mg/kg qd×1d), bortezomib (0.25 or 0.5 mg/kg qd×2d), or combinations thereof for 35 d. Tumor growth was determined via measurement of human immunoglobulin G (hIgG) levels and tumor volume. Results and Conclusions: Vorinostat enhanced the anti‐MM effects of melphalan and bortezomib in vitro. Synergism was observed with vorinostat and melphalan in RPMI8226 and U266 cell lines. Vorinostat 100 mg/kg in combination with melphalan 3 mg/kg resulted in significant inhibition of tumor growth in vivo, compared with control (tumor volume P = 0.0001; hIgG P = 0.0001), single‐agent vorinostat (tumor volume P = 0.0025; hIgG P = 0.0137), and single‐agent melphalan (tumor volume P = 0.0043; hIgG P = 0.0426). Vorinostat also enhanced the antimyeloma effects of bortezomib in vivo. Vorinostat enhances the anti‐MM activity of melphalan and bortezomib in vitro and in vivo. This study provides rationale for further evaluation of vorinostat in combination with chemotherapeutic agents and bortezomib for the treatment of MM. 相似文献
3.
James R. Berenson Ori Yellin Donald Woytowitz Marshall S. Flam Alan Cartmell Ravi Patel Herb Duvivier Youram Nassir Benjamin Eades Christina DiLauro Abaya Jacqueline Hilger Regina A. Swift 《European journal of haematology》2009,82(6):433-439
Background: We conducted a single-arm, multicentre phase 2 study to evaluate bortezomib, ascorbic acid and melphalan (BAM) for patients with newly diagnosed multiple myeloma (MM). Methods: Induction consisted of up to eight 28-d cycles of bortezomib 1.0 mg/m2 on days 1, 4, 8 and 11, plus oral ascorbic acid 1 g and oral melphalan 0.1 mg/kg on days 1–4, followed by maintenance bortezomib 1.3 mg/m2 every 2 wk until progression. Results: Among 35 patients enrolled (median age 70 yr), responses occurred in 23/31 evaluable patients (74%) including five (16%) complete, three (10%) very good partial, six (19%) partial and nine (29%) minimal responses. Six patients (19%) had stable disease. Thus, disease control was achieved in 29 (94%) patients. Median times to first and best responses were 2 and 3 months (ranges 1–5 and 1–7), respectively. Median time to progression was 19 months and median overall survival has not been reached (range 2–23+ months). Grade 3 and 4 adverse events occurred in 17 and 5 patients, respectively; the most common were neutropenia, neuropathy and thrombocytopenia. Conclusions: BAM is an efficacious, well-tolerated and steroid- and immunomodulatory drug (IMiD)-free frontline treatment regimen for MM patients. 相似文献
4.
Eric Sanchez Mingjie Li Jeffrey A. Steinberg Cathy Wang Jing Shen Benjamin Bonavida Zhi‐Wei Li Haiming Chen James R. Berenson 《British journal of haematology》2010,148(4):569-581
The anti‐multiple myeloma (MM) efficacy of bortezomib has led to the development of other proteasome inhibitors (PI), including CEP‐18770 which has shown anti‐MM effects in preclinical studies. However, the efficacy of orally (PO) or intravenously (IV) administered CEP‐18770 in multiple MM models and in combination with conventional anti‐MM therapies has not been evaluated. Herein, we show that CEP‐18770 combined with melphalan or bortezomib induces synergistic inhibition of MM cell viability in vitro. In MM xenograft models, the addition of CEP‐18770 IV to melphalan completely prevented the growth of both melphalan‐sensitive and melphalan‐resistant tumours. The combination of CEP‐18770 IV and bortezomib induced complete regression of bortezomib‐sensitive tumours and markedly delayed progression of bortezomib‐resistant tumours compared to treatment with either agent alone. Single agent CEP‐18770 PO also showed marked anti‐MM effects in these xenograft models. These studies provide strong preclinical rationale for further development of this novel PI in the treatment of MM as a monotherapy as well as combined with either melphalan or bortezomib. 相似文献
5.
Rakesh Popat Heather Oakervee Catherine Williams Mark Cook Charles Craddock Supratik Basu Charles Singer Stephen Harding Nicola Foot Simon Hallam Liz Odeh Simon Joel Jamie Cavenagh 《British journal of haematology》2009,144(6):887-894
This multicenter phase I/II study investigated the maximum tolerated dose (MTD), safety, and efficacy of low dose intravenous (IV) melphalan in combination with bortezomib for patients with relapsed multiple myeloma (MM). Patients received bortezomib 1·3 mg/m2 on days 1, 4, 8, and 11 and escalating doses of IV melphalan (2·5–10·0 mg/m2 ) on day 2 of a 28-day cycle for a maximum of eight cycles. Dexamethasone 20 mg was added for progressive or stable disease. Fifty-three patients were enrolled. The MTD was defined at melphalan 7·5 mg/m2 and bortezomib 1·3 mg/m2 . The overall response rate (ORR) was 68% (23% complete or near-complete responses [CR/nCR]) whilst at the MTD ( n = 33) the ORR was 76% (34% CR/nCR). After median follow-up of 17 months, the median progression free survival was 10 months, rising to 12 months at the MTD ( P < 0·05 vs. non-MTD regimens). The median overall survival was 28 months, but was not yet reached at the MTD. Grade 3/4 adverse events included thrombocytopenia (62%), neutropenia (57%), infection (21%), and neuropathy (15%). Bortezomib and low-dose IV melphalan combination therapy is a safe and highly effective regimen for patients with relapsed MM. These data suggest further investigation of this combination is warranted. 相似文献
6.
目的:观察亚砷酸(ATO)联合维生素C(Vit C)治疗难治性复发性多发性骨髓瘤(MM)的疗效及安全性。方法:15例ⅢA期难治复发MM患者,应用ATO(10mg/d)联合Vit C(2g/d),连用7~14d,每月1次,4~6个周期。结果:总反应率(ORR)60%,完全缓解(CR)13.3%,部分缓解(PR)46.7%,疾病稳定(SD)20%,疾病进展(PD)20%;中位随访时间16个月(6~31个月),中位出现反应时间1个月(1~3个月),中位反应持续时间3个月(1~8个月);10例连续用药14d,反应率(RR)、SD和PD分别为70%、20%和10%。5例连续用药7d,RR、SD和PD分别为40%、20%和40%;两药合用毒性反应轻微,没有超过3级以上的血液学和非血液学毒性反应发生。结论:ATO联合Vit C治疗难治性复发性MM具有一定疗效,毒性反应可耐受。 相似文献
7.
Rousselot P Larghero J Labaume S Poupon J Chopin M Dosquet C Marolleau JP Janin A Brouet JC Fermand JP 《European journal of haematology》2004,72(3):166-171
OBJECTIVES: Pharmacological concentrations of arsenic trioxide (ATO) and organic arsenic melarsoprol induce apoptosis in malignant plasma cells. In an attempt to further document the interest of the arsenic in vivo, we treated severe combined immunodeficient (SCID) mice transplanted with human myeloma cells by ATO or melarsoprol. METHODS : Fifty-two SCID mice were irradiated before intraperitoneal (i.p.) injection of plasma cells from five myeloma patients. Engraftment was assessed by serial measurement of the human monoclonal immunoglobulin G (HuMIgG) concentration in mouse serum. Treatment with ATO (10 microg/g i.p. 5 d a week), melarsoprol (30 microg/g i.p. 5 d a week) or phosphate buffer saline was started when a sustained growth of the tumor cells was demonstrated. RESULTS: Seventeen mice developed the human tumor. A significant decrease in HuMIgG amounts was observed in three of five mice of the ATO group, including two that achieved an apparent complete remission persisting up to 5 months after ATO discontinuation. In these mice, no human plasma cells were detected in tissue samples collected postmortem. Soluble human interleukin-6 receptor amount, measured in mice sera as a surrogate marker of the plasma cell proliferation, varied in parallel with HuMIgG concentration. A significant difference in survival was observed between control and ATO treated mice (113 and 158 d, respectively; P = 0.01) whereas no difference could be evidenced in control and melarsoprol groups. CONCLUSION: Present study confirms in vivo the in vitro effects of ATO on myeloma cells. Delayed relapses were observed suggesting that prolonged or maintenance therapy has to be considered in future clinical trials. Whether or not this will translate into clinically relevant effect of the drug in myeloma patients deserves further consideration. 相似文献
8.
Miki H Ozaki S Nakamura S Oda A Amou H Ikegame A Watanabe K Hiasa M Cui Q Harada T Fujii S Nakano A Kagawa K Takeuchi K Yata K Sakai A Abe M Matsumoto T 《British journal of haematology》2011,155(3):328-339
The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM. 相似文献
9.
目的 探讨三氧化二砷(As2O3)联合IFNα-2a治疗人多发性骨髓瘤(MM)的可行性。方法将人MM细胞系U266细胞株随机分为4组,空白对照组不行特殊处理,As2O3组加入As2O3,IFNα-2a组加入IFNα-2a,As2O3+IFNα-2a组同时加入As2O3及IFNα-2a。孵育48h后用双标记流式细胞术检测细胞凋亡率,用流式细胞仪检测细胞肿瘤坏死因子相关凋亡诱导配体(TRAIL)及其受体表达。结果As2O3+IFNα-2a组细胞凋亡率、TRAIL及其受体表达均显著高于其他三组(P〈0.05),空白对照组TRAIL及其受体表达均显著低于其他三组(P〈0.05)。结论As2O3,及IFNα-2a均可上调TRAIL及其受体表达,促进U266细胞凋亡,且两者有协同作用;此为临床治疗MM提供了新的思路。 相似文献
10.
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma 总被引:15,自引:0,他引:15
Hussein MA Saleh M Ravandi F Mason J Rifkin RM Ellison R 《British journal of haematology》2004,125(4):470-476
Despite aggressive and innovative therapy, patients with multiple myeloma (MM) invariably relapse and die of their disease. New options for non-cytotoxic salvage therapy and additional therapeutic strategies are needed. Arsenic trioxide, an antitumour agent with a multifaceted mechanism of action, induces apoptosis in vitro in MM cell lines and freshly isolated cells from MM patients and, in preliminary studies, displayed clinical activity in patients with late-stage MM. A phase 2, multicentre, open-label study of arsenic trioxide was conducted in 24 MM patients; eight had relapsed and 16 were refractory to prior therapy. Patients received arsenic trioxide 0.25 mg/kg/d for 5 d/week during the first 2 weeks of each 4-week cycle. Sixteen patients had grade 3 or 4 neutropenia and one required antibiotics. Reductions (25% or more) in serum M-protein levels occurred in eight of 24 (33%) patients. An additional six (25%) patients had stable disease. The median time to response was 67.5 d, with a median duration of response of 130 d. Arsenic trioxide therapy lowered serum creatinine levels in two patients with high baseline values. These data indicate that arsenic trioxide is active and reasonably well tolerated as a single-agent salvage therapy, even in patients with late-stage, relapsed and refractory MM. 相似文献
11.
Hjorth M Hjertner Ø Knudsen LM Gulbrandsen N Holmberg E Pedersen PT Andersen NF Andréasson B Billström R Carlson K Carlsson MS Flogegård M Forsberg K Gimsing P Karlsson T Linder O Nahi H Othzén A Swedin A;Nordic Myeloma Study Group 《European journal of haematology》2012,88(6):485-496
Objectives: Thalidomide and bortezomib have been frequently used for second‐line therapy in patients with myeloma relapsing after or refractory to initial melphalan‐based treatment, but no randomized trials have been published comparing these two treatment alternatives. Methods: Thalidomide‐ and bortezomib‐naïve patients with melphalan refractory myeloma were randomly assigned to low‐dose thalidomide + dexamethasone (Thal‐Dex) or bortezomib + dexamethasone (Bort‐Dex). At progression on either therapy, the patients were offered crossover to the alternative drug combination. An estimated 300 patients would be needed for the trial to detect a 50% difference in median PFS between the treatment arms. Results: After inclusion of 131 patients, the trial was prematurely closed because of low accrual. Sixty‐seven patients were randomized to Thal‐Dex and 64 to Bort‐Dex. Progression‐free survival was similar (median, 9.0 months for Thal‐Dex and 7.2 for Bort‐Dex). Response rate was similar (55% for Thal‐Dex and 63% for Bort‐Dex), but time to response was shorter (P < 0.05) and the VGPR rate higher (P < 0.01) for Bort‐Dex. Time‐to‐other treatment after crossover was similar (median, 13.2 months for Thal‐Dex and 11.2 months for Bort‐Dex), as was overall survival (22.8 months for Thal‐Dex and 19.0 for Bort‐Dex). Venous thromboembolism was seen in seven patients and cerebrovascular events in four patients in the Thal‐Dex group. Severe neuropathy, reactivation of herpes virus infections, and mental depression were more frequently observed in the Bort‐Dex group. In the quality‐of‐life analysis, no difference was noted for physical function, pain, and global quality of life. Fatigue and sleep disturbances were significantly more prevalent in the Bort‐Dex group. Conclusions: Thalidomide (50–100 mg daily) in combination with dexamethasone seems to have an efficacy comparable with that of bortezomib and dexamethasone in melphalan refractory myeloma. However, the statistical strength of the results in this study is limited by the low number of included patients. 相似文献
12.
13.
The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As2O3) is undefined. Three APL patients relapsing from As2O3-induced remission were studied. Re-treatment with As2O3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As2O3 and all-trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow-up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse. 相似文献
14.
15.
Nishihori T Alekshun TJ Shain K Sullivan DM Baz R Perez L Pidala J Kharfan-Dabaja MA Ochoa-Bayona JL Fernandez HF Yarde DN Oliveira V Fulp W Han G Kim J Chen DT Raychaudhuri J Dalton W Anasetti C Alsina M 《British journal of haematology》2012,157(5):553-563
We conducted a Phase 1/2 study of bortezomib administered in combination with high-dose melphalan followed by tandem autologous transplants in patients with primary resistant multiple myeloma. Thirty patients received two cycles of salvage bortezomib followed by stem cell mobilization with granulocyte colony-stimulating factor and harvest. Melphalan 100 mg/m(2) per day on two consecutive days was administered, immediately followed by one dose of bortezomib (dose escalation) and stem cell infusion. The median beta 2-microglobulin was 4·35 mg/l (range: 1·8-11·4); albumin was 37 g/l (range: 3·1-4·9); high-risk karyotypes were noted in 45% of patients. The maximum planned dose of bortezomib at 1·3 mg/m(2) was well tolerated and a formal maximum tolerated dose was not determined. The peak of best overall response (≥partial response) and complete response rates after tandem transplants were 84% and 36%, respectively. With a median follow-up of 48 months, the median progression-free survival was 15 [95% confidence interval (CI): 11-21] months and the median overall survival was 35 (95% CI: 22-43) months. Correlative studies demonstrated decreased expression of BRCA2 (P = 0·0072) and FANCF (P = 0·0458) mRNA following bortezomib treatment. Bortezomib combined with high-dose melphalan is a well-tolerated conditioning with some activity in patients with resistant myeloma. 相似文献
16.
17.
Combination therapy with bortezomib,continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Esther G. M. de Waal Linda de Munck Mels Hoogendoorn Gerhard Woolthuis Annette van der Velden Yvonne Tromp Edo Vellenga Sjoerd Hovenga 《British journal of haematology》2015,171(5):720-725
Combination therapy for longer periods but at low dose might be an effective and tolerable manner to treat patients with relapsed multiple myeloma (MM). We used bortezomib, dexamethasone and low‐dose oral cyclophosphamide as an induction regimen, followed by 1 year of maintenance consisting of bortezomib and cyclophosphamide. Relapsed MM patients were treated with six cycles of bortezomib twice weekly, cyclophosphamide 50 mg daily and dexamethasone. Maintenance therapy was given for 1 year. Primary endpoints were toxicity during re‐induction and maintenance therapy. Secondary endpoints were response to treatment and progression‐free (PFS) and overall survival (OS). This study included 59 patients. Myelosuppression and neuropathy were the most common side effects. Median follow‐up was 27·1 (0·46–54·4) months with an overall response of 71%, and a very good partial response or more of 33%. During maintenance, improved responsiveness was observed in 19% of the patients. The median PFS was 18·4 months (range 0·13–43·5) and the median OS was 28·1 months (range 0·13–54·4). In conclusion, our study demonstrates that treatment with bortezomib, dexamethasone and low‐dose cyclophosphamide is an effective and manageable regimen. Adding 1 year of maintenance was feasible, with limited side effects and an increased response rate. 相似文献
18.
Habte Yimer Jason Melear Edward Faber William I. Bensinger John M. Burke Mohit Narang Don Stevens Sriya Gunawardena Yana Lutska Keqin Qi Jon Ukropec Ming Qi Thomas S. Lin Robert M. Rifkin 《British journal of haematology》2019,185(3):492-502
This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4–8 induction cycles of bortezomib 1·5 mg/m2, cyclophosphamide 300 mg/m2 and dexamethasone 40 mg weekly. Intravenous daratumumab 16 mg/kg was administered as approved except for a split-first dose in Cycle 1. Eligible patients underwent autologous stem cell transplantation. All patients received ≤12 daratumumab maintenance doses monthly. Eighty-six NDMM and 14 RMM patients received ≥1 treatment dose. In NDMM patients, very good partial response or better (≥VGPR) and overall response rates after 4 induction cycles were 44% (primary endpoint) and 79%, respectively, and 56% and 81% at end of induction. The 12-month progression-free survival (PFS) rate was 87%. Efficacy was also observed in RMM patients. Fatigue (59%) and neutropenia (13%) were the most frequent treatment-emergent adverse event (TEAE) and grade 3/4 TEAE, respectively. Infusion reactions occurred in 54% of patients, primarily during the first dose, and were mild (2% grade 3). The first 2 daratumumab infusions were 4·5 and 3·8 h (median). Overall, D-VCd was well tolerated, split-first daratumumab dosing was feasible, the ≥VGPR rate after 4 cycles was 44% and the 1-year PFS rate was 87%. 相似文献
19.
目的:探讨沙利度胺联合三氧化二砷治疗骨髓增生异常综合征的有效性和安全性。方法:42例骨髓增生异常综合征患者分为2组,治疗组使用沙利度胺和三氧化二砷,对照组接受促红细胞生成素及输血为主的对症支持治疗。比较2组的疗效,观察药物的不良反应。结果:治疗组20例完全缓解1例,部分缓解3例,血液学改善11例,总有效率75%,未发现严重不良反应;对照组22例无完全缓解,部分缓解1例,血液学改善8例,总有效率40.91%,与治疗组比较,差异有统计学意义(P<0.05)。结论:沙利度胺联合三氧化二砷治疗骨髓增生异常综合征有效率高,不良反应轻微,耐受性好。 相似文献